Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TQB6411 injection in previously treated recurrent or metastatic esophageal cancer
CTR20260385Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB6411 in esophageal cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
TQB6411
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on CTR20260385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260385.